Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 17-85 Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan.
Bioorg Med Chem. 2012 Jan 15;20(2):714-33. doi: 10.1016/j.bmc.2011.12.008. Epub 2011 Dec 13.
Herein, we describe the design, synthesis, and structure-activity relationships of novel benzylpyrazole acylsulfonamides as non-thiazolidinedione (TZD), non-carboxylic-acid-based peroxisome proliferator-activated receptor (PPAR) γ agonists. Docking model analysis of in-house weak agonist 2 bound to the reported PPARγ ligand binding domain suggested that modification of the carboxylic acid of 2 would help strengthen the interaction of 2 with the TZD pocket and afford non-carboxylic-acid-based agonists. In this study, we used an acylsulfonamide group as the ring-opening analog of TZD as an isosteric replacement of carboxylic acid moiety of 2; further, preliminary modification of the terminal alkyl chain on the sulfonyl group gave the lead compound 3c. Subsequent optimization of the resulting compound gave the potent agonists 25c, 30b, and 30c with high metabolic stability and significant antidiabetic activity. Further, we have described the difference in binding mode of the carboxylic-acid-based agonist 1 and acylsulfonamide 3d.
在这里,我们描述了新型苯并吡唑酰基磺酰胺作为非噻唑烷二酮(TZD)、非羧酸类过氧化物酶体增殖物激活受体(PPAR)γ激动剂的设计、合成和构效关系。基于对接模型分析,我们将内部分子弱激动剂 2 与报道的 PPARγ 配体结合域结合,表明对 2 的羧酸的修饰将有助于加强 2 与 TZD 口袋的相互作用,并提供非羧酸类激动剂。在这项研究中,我们使用酰基磺酰胺基团作为 TZD 的开环类似物,作为 2 中羧酸部分的等排体替代物;进一步,对磺酰基上末端烷基链进行初步修饰得到了先导化合物 3c。随后对得到的化合物进行优化,得到了具有高代谢稳定性和显著抗糖尿病活性的强效激动剂 25c、30b 和 30c。此外,我们还描述了基于羧酸的激动剂 1 和酰基磺酰胺 3d 的结合模式的差异。